In last trading session, Pacira BioSciences Inc (NASDAQ:PCRX) saw 0.47 million shares changing hands with its beta currently measuring 0.55. Company’s recent per share price level of $25.72 trading at -$0.28 or -1.08% at ring of the bell on the day assigns it a market valuation of $1.19B. That closing price of PCRX’s stock is at a discount of -23.13% from its 52-week high price of $31.67 and is indicating a premium of 56.61% from its 52-week low price of $11.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.65 million shares which gives us an average trading volume of 909.35K if we extend that period to 3-months.

For Pacira BioSciences Inc (PCRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.43. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.6 in the current quarter.

Pacira BioSciences Inc (NASDAQ:PCRX) trade information

Upright in the red during last session for losing -1.08%, in the last five days PCRX remained trading in the green while hitting it’s week-highest on Monday, 04/21/25 when the stock touched $25.72 price level, adding 3.78% to its value on the day. Pacira BioSciences Inc’s shares saw a change of 36.52% in year-to-date performance and have moved 4.34% in past 5-day. Pacira BioSciences Inc (NASDAQ:PCRX) showed a performance of 5.32% in past 30-days. Number of shares sold short was 5.93 million shares which calculate 6.3 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 24.5 to the stock, which implies a fall of -4.98% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 48. It follows that stock’s current price would jump 53.34% in reaching the projected high whereas dropping to the targeted low would mean a gain of 53.34% for stock’s current value.

Pacira BioSciences Inc (PCRX) estimates and forecasts

This year revenue growth is estimated to rise 7.41% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 175.88M for the same. And 6 analysts are in estimates of company making revenue of 187.48M in the next quarter. Company posted 167.12M and 178.02M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -51.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -9.41% while estimates for its earnings growth in next 5 years are of 12.47%.

Pacira BioSciences Inc (NASDAQ:PCRX)’s Major holders

Insiders are in possession of 3.09% of company’s total shares while institution are holding 108.02 percent of that, with stock having share float percentage of 111.47%. Investors also watch the number of corporate investors in a company very closely, which is 108.02% institutions for Pacira BioSciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at PCRX for having 8.01 million shares of worth $229.08 million. And as of 2024-06-30, it was holding 17.3406 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.08 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.0123 of outstanding shares, having a total worth of $145.48 million.

On the other hand, Pacer Funds Trust-Pacer US Small Cap Cash Cows ETF and iShares Trust-iShares Core S&P Small-Cap ETF are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 3.07 shares of worth $78.92 million or 6.63% of the total outstanding shares. The later fund manager was in possession of 2.85 shares on Mar 31, 2025 , making its stake of worth around $73.42 million in the company or a holder of 6.17% of company’s stock.